← Eichor
Study identifier: NCT06054880 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency

Condition: Ureter Injury  ·  Sponsor: Prove pharm

PhasePhase 4
Planned participants116
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

This is a randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Bludigo when used as an aid in the determination of ureteral patency.

This description comes directly from the study's public registry record.

Talk to the study team

Michelle Boytim, Ph.D.  ·  610-850-7115  ·  michelle.boytim@provepharm.com

Always discuss trial participation with your own doctor first.

Locations (1)

Albany Medical CenterAlbany, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06054880